SAB Biotherapeutics, Inc. (SABSW) NASDAQ
0.02
+0.0016(+9.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
SAB Biotherapeutics, Inc.
Address
2100 East 54th Street North
Sioux Falls, SD 33140
United States of America (the)
Phone
605-679-6980
Sector
Healthcare
Industry
Biotechnology
Employees
63
First IPO Date
October 25, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Samuel J. Reich | CEO & Director | 846,462 | 1975 |
| Christoph Bausch | Executive Vice President & Chief Operating Officer | 609,000 | 1971 |
| Lucy To | Executive Vice President & Chief Financial Officer | 684,034 | 1986 |
| Eddie Joe Sullivan | Co-Founder, President & Director | 746,500 | 1967 |
| Alexandra Kropotova | Executive Vice President & Chief Medical Officer | 832,249 | 1973 |
| Carlos N. Carillo | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Cristi Barnett | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Hua Wu | Senior Vice President of Product Development | 0 | N/A |
| Angie Parizek | Senior Vice President of Clinical Operations | 0 | N/A |
| Catherine DeRose | Vice President of Human Resources | 0 | N/A |
Description
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
